retatrutide triple agonist glp-1 gip glucagon phase 2 results Eli Lilly's shows promising weight loss in 3 trial Diagram showing the mechanism of

Frequently Asked Questions What are the best foods to eat on retatrutide to reduce nausea

The program offers personalized support and counseling from a team of professionals who design a custom treatment plan based on each individual's unique needs and goals

Research Priority: Scientists have focused more intensively on GLP-1 and GLP-2 due to their obvious therapeutic potential

However, starting in July 2026, a new program called the BALANCE Model may give eligible Medicare Part D beneficiaries access to certain GLP-1 weight loss medications for a $50 copay

Orenstein et al., 2013)

Retatrutide vs tirzepatide vs semaglutide Category Receptor targets Retatrutide GLP-1 + GIP + Glucagon (triple) Tirzepatide GLP-1 + GIP (dual) Semaglutide GLP-1 only (single) Category Half-life Retatrutide ~6 days Tirzepatide ~5 days Semaglutide ~7 days Category Dose frequency Retatrutide Once weekly Tirzepatide Once weekly Semaglutide Once weekly Category Max studied dose Retatrutide 12 mg/week Tirzepatide 15 mg/week Semaglutide 2.4 mg/week Category Peak weight loss in trials Retatrutide -28.7% at 68 weeks (Phase 3 TRIUMPH-4) Tirzepatide -22.5% at 72 weeks (SURMOUNT-1) Semaglutide -15.8% at 68 weeks (STEP-1) Category FDA status (June 2026) Retatrutide Investigational, Phase 3 Tirzepatide Approved (obesity + T2D) Semaglutide Approved (obesity + T2D) Category Liver fat Retatrutide Up to 82% reduction (Phase 2 substudy) Tirzepatide Significant reduction Semaglutide Moderate reduction Category Unique angle Retatrutide Triple agonism may raise energy expenditure via glucagon pathway Tirzepatide Dual agonism balances effect and tolerability Semaglutide Longest clinical track record